Home2018-11-29T12:30:20+00:00
What we do—

Changing the world

UCLB is the commercialisation company of UCL and its partner NHS Trusts. We bring to market truly world-leading, world-changing technologies, innovations that have a real and positive impact on people’s lives.

Read More
Latest news—

£438 million investment for UCL gene therapy spinouts

UCL spinout Orchard Therapeutics, a biotechnology company dedicated to transforming the lives of patients with rare disorders through innovative gene therapies, has raised $225 million (£173 million) through its initial public offering. The funding success adds to an unprecedented summer that saw UCL spinout companies raise £265 million of investment which could transform patient outcomes.

Read More
Featured Technology—

Novel method of analysis of stroke data

Stroke is the leading cause of adult disability in the UK at an estimated cost of £7 billion a year. UCL has developed a system for predicting clinical outcomes so as to provide advance information on the optimum clinical management of each patient.
Read more
Spotlight—

UCLB Marks 25 Years of Innovation

As this year marks our 25th anniversary, it provides the perfect time to look back on some of the remarkable achievements leading up to this point.

Read More
Featured Technology—

SnakeGrid

SnakeGrid is a way of developing low-distortion coordinate systems for large engineering projects.

Read more

Latest news and highlights

Read More News

SmartTarget® technology pinpoints biopsies to detect prostate cancer

/ UCLB News
Medical software developed at UCL that overlays tumour information from MRI scans onto ultrasound images can help guide surgeons conducting ...

UCL Spinouts Feature in Industrial Strategy Life Sciences Sector Deal Two

/ UCLB News
The government has published the second Life Sciences Sector Deal, which outlines public and private sector investments into the sector ...

Freeline Presents Data on AAV-based Gene Therapy for Haemophilia B at the 60th ASH Annual Meeting

/ UCLB News
A single infusion of FLT180a resulted in sustained mean Factor IX activity of 45%, with no toxicity or adverse effects, ...

UCL Technology Fund invests in IGEM Therapeutics

/ UCLB News
UCLTF has invested in a series A round for immuno-oncology company IGEM Therapeutics. The £5million funding round also included investment ...

FIND THE RIGHT MATCH

Whether you’re an academic or looking for technologies, find your UCLB contact here.

 

Bringing innovation to life

0
Active spinouts
0
Active licences in 2017
0
Drug discoveries
0
New patent applications